An observational study in Burn, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Burns with a site in France — 6 open to participants now, 7 under way, 2 of them phase 3. Burns · France.
Among the 32 studies in Burns with a site in France, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2025, is one of 10 observational ones, and was the 30th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →6 of the 32 studies in Burns with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18–80
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
CUTISS AG · Sites in France, Belgium, Germany and 6 more countries
Ages 12+
Centre Hospitalier Régional Metz-Thionville · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 327 is above the median of 64 across 163 observational studies indexed under Burns.
Median enrollment 27 across the 22 interventional studies, 72 across the 10 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 32 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 6 studies filed under Burns — fewer than ten, so there is no comparison to draw.
4 of the studies in Burns with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06745557Phase 3CUTISS AGPhase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents | 2027-06-30 |
| NCT06487910Centre Hospitalier Régional Metz-ThionvilleDifferential Pressure Distribution Orthosis by 3D Printing Process in the Treatment of Post-burn Hypertrophic Scarring | 2027-01-10 |
| NCT04264065Assistance Publique - Hôpitaux de ParisAlbumin and Prognosis of Severely Patients Burns | 2027-01-16 |
| NCT06469970Centre Hospitalier Régional Metz-ThionvilleEvolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults | 2027-03-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 32 studies in Burns with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.
Adult patients with burn injury
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Burn patients
Exclusion Criteria:
Other: Biological sampling
Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites) At day 0, day 3, day 7, day 14, day 21
Invasive fungal disease (IFD) onset during hospitalisation time
Proven IFD according to EORTC/MSGERC criteria applicable for invasive candidiasis. Putative invasive mold infection is defined with ≥ 2 positive culture from skin biopsy/bronchoalveolar lavage or ≥ 2 positive blood specific qPCR (aspergilosis, mucorales, fusariosis) or a combination of both. Possible invasive mold infection is defined with only one positive mycological criterion.
Time frame: Up to 18 months
Overall survival
Time frame: At day 30
Overall survival
Time frame: At day 90
Hospital mortality
Time frame: Up to 18 months
Incidence of organ failure during hospitalisation
* Acute respiratory distress syndrome defined by the modified Berlin criteria, or * Acute kidney injury as defined by the KDIGO consensus, or * Septic shock and doses of catecholamines defined by SEPSIS-3
Time frame: Up to 18 months
Severity score at admission
SAPS 2 : Simplified Acute Physiology Score II The score can range from 0 to 163. Higher score indicates more severe illness and a higher risk of mortality. Lower score indicates less severe illness and a lower risk of mortality.
Time frame: At inclusion
Severity score at admission
ABSI Acute Bowel Ischemia Severity Index The score ranges from 0 to 10. A higher score indicates a more severe case and a higher risk of mortality.
Time frame: At inclusion
Severity score at admission
SOFA score : Sequential Organ Failure Assessment The score can range from 0 to 24, with higher scores indicating more severe organ failure and a worse prognosis.
Time frame: At inclusion
Number of days without renal replacement therapy
Time frame: At day 30
Number of days without mechanical ventilation
Time frame: At day 30
Length of stay in Intensive Care Unit
Time frame: Up to 18 months
Length of stay in hospital
Time frame: Up to 18 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Oct 2030, 66 months after the start.
Of 58 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 66 months is above that.
Counting every sponsor, half of 70 studies reached it within 24 months; a quarter within 14 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →